

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 14, 2023**

**APPLIED MOLECULAR TRANSPORT INC.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-39306  
(Commission  
File Number)

81-4481426  
(IRS Employer  
Identification No.)

Address not Applicable<sup>(1)</sup>  
(Address of principal executive offices, including zip code)

(650) 392-0420  
(Registrant's telephone number, including area code)

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, par value \$0.0001 per share	AMTI	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

<sup>1</sup> We are a remote-only company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, or the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, any stockholder communication required to be sent to our principal executive offices may be directed to the agent for service of process at the following address: Applied Molecular Transport Inc., c/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Wilmington, DE 19801, or to the email address: corporate.secretary@appliedmt.com.

---

---

---

**Item 2.02 Results of Operations and Financial Conditions.**

On August 10, 2023, Applied Molecular Transport Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

d. Exhibits.

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press Release of Applied Molecular Transport Inc. dated August 14, 2023</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**APPLIED MOLECULAR TRANSPORT INC.**

Date: August 14, 2023

By: /s/ Shawn Cross  
Shawn Cross  
Chief Executive Officer and Chair of the Board of Directors

## APPLIED | MOLECULAR | TRANSPORT

**Applied Molecular Transport Reports Second Quarter 2023 Financial Results***Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company**Cash and Cash Equivalents of \$22.5 million, as of June 30, 2023*

SOUTH SAN FRANCISCO, Calif., August 14, 2023 — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023.

**Financial Results for the Second Quarter Ended June 30, 2023**

**Research and development (R&D) expenses.** Total R&D expenses for the second quarter of 2023 were \$2.6 million, compared to \$22.8 million for the same period in 2022. The overall decrease was attributable to a restructuring of operations, related reductions in workforce implemented in March 2023 and discontinuing all research and development activities.

**General and administrative (G&A) expenses.** Total G&A expenses for the second quarter of 2023 were \$7.0 million, compared to \$9.4 million for the same period in 2022. The overall decrease was attributable to a restructuring of operations and related reductions in workforce implemented in March 2023.

**Restructuring, impairment, and related charges.** Total restructuring, impairment, and related charges for the second quarter of 2023 were \$8.1 million, primarily comprised of write offs of right-of-use assets and related leasehold improvements upon the company vacating leased premises for its corporate headquarters and manufacturing warehouse. Restructuring charges for the same period in 2022 were \$3.8 million, primarily comprised of severance payments and other employee-related separation costs associated with a reduction in workforce implemented in May 2022.

**Net loss.** Net loss for the second quarter of 2023 was \$17.3 million, compared to \$35.9 million for the same period in 2022. Operating expenses for the second quarter of 2023 were \$17.7 million and interest income was \$0.4 million.

**Cash and cash equivalents.** As of June 30, 2023, cash and cash equivalents were \$22.5 million.

**About Applied Molecular Transport Inc.**

AMT is a clinical-stage biopharmaceutical company that has a proprietary technology platform that enables the design of novel biologic product candidates in patient-friendly oral dosage forms. The company has completed four Phase 2 clinical trials for its most advanced product candidate, AMT-101.

For additional information on AMT, please visit [www.appliedmt.com](http://www.appliedmt.com).

**Forward-Looking Statements**

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements including statements relating to AMT's plans, expectations, forecasts and future events. Such forward-looking statements include, but are not limited to, statements regarding the ability of AMT to enter into a strategic transaction and sufficiency of AMT's cash resources. In some cases, you can identify forward-looking statements by terminology such as "believe," "estimate," "intend," "may," "plan," "potentially," "will," "expect," "enable," "likely" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual events, trends or results could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements based on various factors. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in AMT's Annual and Quarterly Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission (the "SEC"), and AMT's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and AMT assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

**Applied Molecular Transport Inc.**  
**Condensed Balance Sheets**  
**(unaudited)**  
(in thousands)

	June 30, 2023	December 31, 2022
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 22,457	\$ 61,145
Prepaid expenses	860	2,688
Other current assets	—	186
Total current assets	23,317	64,019
Property and equipment, net	39	8,183
Operating lease right-of-use assets	1,477	33,222
Finance lease right-of-use assets	—	584
Restricted cash	—	916
Other assets	127	522
Total assets	\$ 24,960	\$ 107,446
<b>Liabilities and stockholders' equity</b>		
Current liabilities:		
Accounts payable	\$ 156	\$ 1,583
Accrued expenses	2,202	8,660
Lease liabilities, operating lease - current	1,458	4,639
Lease liabilities, finance lease - current	—	205
Total current liabilities	3,816	15,087
Lease liabilities, operating lease	254	31,228
Lease liabilities, finance lease	—	49
Other liabilities	244	244
Total liabilities	4,314	46,608
Commitments and contingencies		
Stockholders' equity:		
Common stock	4	4
Additional paid-in capital	431,862	426,804
Accumulated deficit	(411,220)	(365,970)
Total stockholders' equity	20,646	60,838
Total liabilities and stockholders' equity	\$ 24,960	\$ 107,446

**Applied Molecular Transport Inc.**  
**Condensed Statements of Operations**  
**(unaudited)**

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2023	2022	2023	2022
Operating expenses:				
Research and development	\$ 2,558	\$ 22,802	\$ 15,546	\$ 54,041
General and administrative	7,045	9,433	13,797	20,770
Restructuring, impairment, and related charges	8,129	3,787	16,872	3,787
Total operating expenses	17,732	36,022	46,215	78,598
Loss from operations	(17,732)	(36,022)	(46,215)	(78,598)
Interest income, net	419	75	998	72
Other income (expense), net	(20)	2	(33)	6
Net loss	\$ (17,333)	\$ (35,945)	\$ (45,250)	\$ (78,520)
Net loss per share, basic and diluted	\$ (0.44)	\$ (0.93)	\$ (1.15)	\$ (2.03)
Weighted-average shares of common stock outstanding, basic and diluted	39,333,046	38,748,741	39,261,122	38,695,350

Refer to the Company's applicable SEC filings for previously reported periods.

**Investor Relations and Media Contact:**

Alexandra Santos

Wheelhouse Life Science Advisors

[asantos@wheelhousesa.com](mailto:asantos@wheelhousesa.com)